Research programme: dendritic cell monoclonal antibodies - Alexion/UMC Nijmegen

Drug Profile

Research programme: dendritic cell monoclonal antibodies - Alexion/UMC Nijmegen

Alternative Names: Anti-DC-SIGN antibodies; Anti-L-SIGN antibodies; Cancer vaccine - Alexion/UMC Nijmegen

Latest Information Update: 16 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University Medical Centre of Nijmegen
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jan 2007 Preclinical development is ongoing for Cancer
  • 29 Sep 2005 This programme is still in active development
  • 18 Nov 2003 Preclinical trials in Cancer in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top